BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625), developer of the first-of-its-kind artificial liver device, today announced the appointment of its Vice President, Research & Development, Dr. Christopher W. Kemp, a proven cell biology research scientist and successful entrepreneur with over thirty years of experience.
